Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | CA1 | P00915 | 8/20 | 0.56 |
| ▸ | CA2 | P00918 | 8/20 | 0.56 |
| ▸ | CA12 | O43570 | 5/20 | 0.56 |
| ▸ | CA9 | Q16790 | 5/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | FPR3 | P25089 | 2/20 | 0.48 |
| ▸ | FPR2 | P25090 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17680506 | 0.96 | ALDH1A1 (0.55) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL5308838 | 0.91 | CA1 (0.50) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL5094941 | 0.89 | ALDH1A1 (0.60) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL29764347 | 0.88 | CA1 (0.56) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL30371850 | 0.86 | CA1 (0.52) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL4950063 | 0.86 | ALDH1A1 (0.61) | ALDH1A1GAATSHRPKM | |
| SCHEMBL7395957 | 0.85 | ALDH1A1 (0.50) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL6038379 | 0.84 | ALDH1A1 (0.58) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL4942519 | 0.84 | ALDH1A1 (0.56) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL569562 | 0.83 | CA12 (0.65) | ALDH1A1CA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190821-A1 | SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF | TRIANA BIOMEDICINES INC (US) | 2024-06-13 | — | — | US | disclosed |
| WO-2022169755-A1 | SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL) BENZENESULFONAMIDES AND USES THEREOF | TRIANA BIOMEDICINES, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
| WO-2022169755-A1 | SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL) BENZENESULFONAMIDES AND USES THEREOF | TRIANA BIOMEDICINES, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190821-A1 | SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF | PACSIN2, TPX2, PRSS12 | ALDH1A1 3608/4885CA1 4029/4885CA2 3857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.